Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACT Dr Heinz Schwer ADDRESS Lena-Christ-Str. 48 82152 Martinsried/Planegg Germany TELEPHONE 089 89927 152 FAX 089 89927 5152 EMAIL Heinz.schwer@morphosys.com YEAR FOUNDED 1992 MorphoSys AG www.morphosys.com FINANCIAL SUMMARY Report for the first six month of 2012: Group Revenues: 33.0 m Eur EBIT (1.9) m Eur Net (Loss)/Profit (1.0) m Eur EPS, diluted in Eur (0.04) COMPANY PROFILE MorphoSys has developed and established one of the world’s leading fully human antibody technologies. Numerous partnerships with well-known companies from the pharmaceutical and biotechnology sector, such as Boehringer Ingelheim, Daiichi Sankyo, Merck, Novartis, Pfizer and Roche illustrate our success. With the help of our proprietary, industry-leading antibody technologies, more than 400 employees at four locations worldwide are dedicated to engineering the medicines and diagnostics of tomorrow. The international teams collaborate closely to streamline and coordinate product research and development with all its accompanying processes. MANAGEMENT The Management Board and Supervisory Board of MorphoSys are committed to creating significant value for all employees, shareholders, customers and partners through a sustainable business strategy balancing short-term and long-term growth potential. The Board Dr Simon Moroney, CEO Dr Arndt Schottelius, CDO Jens Holstein, CFO Dr Marlies Sproll, CSO t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACT Tom Johnston Chief Executive Officer ADDRESS Mucosis B.V. L.J. Zielstraweg 1 9713 GX, Groningen The Netherlands TELEPHONE +31 (50) 8200050 (T) +31 (6) 55320948 (M) FAX +31 (50) 8200051 EMAIL tom.johnston@mucosis.com YEAR FOUNDED 2006 Mucosis B.V. www.mucosis.com FINANCIAL SUMMARY Series A: €3,000,000 (2007) Inn.Credit: €3,000,000 (2010) Current Investors: • Biogeneration Ventures • MedSciences Capital • N.V. NOM COMPANY PROFILE About Mucosis Mucosis B.V. is a Dutch biotechnology company with a proprietary platform technology, Mimopath, on which it develops mucosal vaccines with improved efficacy. Mucosis’s lead products are FluGEM, a vaccine to prevent influenza; PneuGEM, a vaccine to prevent diseases caused by pneumococcal bacteria; and SynGEM, a vaccine to prevent RSV viral infections. Mimopath-based vaccines can be administered needle-free in the nose and mouth, evoking a more natural immune response with a broader base of protection. About Mimopath technology The Mimopath technology is based on Lactococcus lactis, a safe bacterium commonly used in the food industry. Mucosis has developed a robust technique to formulate the L. lactis bacteria into non-living bacteriumlike particles (BLPs) that can be loaded with antigens from viral, bacterial, parasitic or tumor origin. The antigencovered BLPs form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These vaccines raise protective immunity by activation of both the innate and the adaptive immune system. MANAGEMENT Senior Management Thomas Johnston, CEO Kees Leenhouts, CSO Roberto Grimaldi, CMO Jolande Schoemaker, QA-officer & Qualified Person Board of Directors John Lambert, Chairman Barry Buckland Annemieke Wouterse Willem Hazenberg Otto Postma t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2:
B I O T E C H I N E U R O P E I N V
Page 3 and 4:
Events Diary For regular updates, s
Page 5 and 6:
Speakers Alexey Eliseev, Managing D
Page 7 and 8:
Speakers Blake M. Paterson, Co-Foun
Page 9 and 10:
Speakers David Slack, Head of Corpo
Page 11 and 12:
Speakers Frank Grams, VP, Head Alli
Page 13 and 14:
Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16:
Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67: CONTACT Maaike Vogelezang Managemen
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84: CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86: CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88: ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90: CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92: CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94: CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96: CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98: CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100: CONTACTS Piers Morgan Chief Financi
Page 101 and 102: CONTACT Jakob Knudsen Chief Executi
Page 103 and 104: CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106: Supporting Organisations Citigate D
Page 107 and 108: Supporting Organisations Life Scien
Page 109 and 110: Supporting Organisations Swiss Biot
Page 111 and 112: Supporting Organisations Torreya Pa
Page 113: B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?